Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Group 1: Product Development - KC1036 is a self-developed Class 1 innovative chemical drug with global intellectual property rights held by the company [1] - The drug exerts anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL, demonstrating strong vascular targeting of VEGFR and inhibiting tumor cell growth [1] - Inhibiting AXL can enhance the host's anti-tumor immune response, thereby preventing immune evasion by tumors [1] Group 2: Clinical Research - KC1036 is currently undergoing clinical research for multiple indications, including gastrointestinal tumors, thymic tumors, and pediatric rhabdomyosarcoma [1] - Over 300 subjects have been enrolled in the clinical studies for KC1036 to date, with existing results showing outstanding anti-tumor activity, as well as good safety and tolerability [1]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative chemical drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Group 1: Product Development - KC1036 is a self-developed innovative chemical drug with global intellectual property rights held by the company [1] - The drug exhibits anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL, demonstrating strong vascular targeting and tumor cell growth suppression [1] - Clinical studies for KC1036 are ongoing for various indications, including gastrointestinal tumors, thymic tumors, and pediatric Ewing sarcoma, with over 300 subjects enrolled to date [1] Group 2: Clinical Trial Results - Preliminary clinical research results indicate significant anti-tumor activity, along with good safety and tolerability profiles for KC1036 [1]

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-054 北京康辰药业股份有限公司 关于 KC1036 联合 PD-1 抗体和含铂化疗一线治疗晚期复发或 转移性食管鳞癌获得临床试验通知书的公告 二、KC1036 研发进展 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京康辰药业股份有限公司（以下简称"公司"）收到国家药品监督管 理局核准签发的化学 1 类创新药 KC1036 片关于"KC1036 联合 PD-1 抗体和含铂 化疗一线治疗晚期复发或转移性食管鳞癌"的临床试验通知书，并将于近期开展临 床试验。现将主要相关情况公告如下： 一、本次批准的基本情况 药品名称：KC1036 片 规格：20 mg、30 mg 受理号：CXHL2500740、CXHL2500741 拟开展适应症：KC1036 联合 PD-1 抗体和含铂化疗一线治疗晚期复发或转移 性食管鳞癌 KC1036 是公司自主研发的化学药品 1 类创新药，公司拥有该产品的全球知识 产权。KC1036 通过抑制 VEGFR2、AXL 等多靶点实 ...

Core Viewpoint - Kangchen Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its innovative chemical drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Group 1: Product Development - KC1036 is a self-developed innovative chemical drug classified as a Class 1 new drug [1] - The drug targets multiple pathways by inhibiting VEGFR2 and AXL to achieve anti-tumor activity [1] - KC1036 exhibits strong vascular targeting of VEGFR, inhibiting tumor cell growth, and improving host anti-tumor immune response by suppressing AXL, thus preventing immune evasion by tumors [1] Group 2: Clinical Research - Clinical trials for KC1036 are set to commence shortly, with over 300 subjects already enrolled in ongoing clinical studies for multiple indications [1]

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]

Group 1 - The stock prices of Mengke Pharmaceutical dropped over 10% [1] - Borui Pharmaceutical and Baicheng Pharmaceutical experienced declines of over 7% [1] - Other companies such as Yuekang Pharmaceutical, Kangchen Pharmaceutical, Yuandong Biological, and Fuxiang Pharmaceutical also saw significant drops in their stock prices [1]

9月25日，康辰药业跌5.01%，截至发稿，报52.15元/股，成交1.37亿元，换手率1.61%，总市值83.10亿 元。 杨珂累计任职时间5年137天，现任基金资产总规模14.45亿元，任职期间最佳基金回报55.92%， 任职期 间最差基金回报-13.42%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，信达澳亚基金旗下1只基金重仓康辰药业。信澳健康中国混合A（003291）二季度持有股数 73.06万股，占基金净值比例为3.38%，位居第十大重仓股。根据测算，今日浮亏损失约200.91万元。 信澳健康中国混合A（003291）成立日期2017年8月18日，最新规模5.34亿。今年以来收益34.35%，同 类排名2667/8173；近一年收益43.89%，同类排名3547/8003；成立以来收益155.4%。 信澳健康中国混合A（003291）基金经理为李君周、杨珂。 截至发稿，李君周累计任职时间112天，现任基金资产总规模6.8亿元 ...

Core Viewpoint - Kangchen Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 155.22%, indicating strong market performance and investor interest [1][2]. Group 1: Stock Performance - On September 17, Kangchen Pharmaceutical's stock price decreased by 2.04%, closing at 58.50 CNY per share, with a trading volume of 165 million CNY and a turnover rate of 1.76% [1]. - The company's total market capitalization is 9.322 billion CNY [1]. - Year-to-date, the stock has risen by 155.22%, with a 12.13% increase over the last five trading days, an 8.35% increase over the last 20 days, and an 81.96% increase over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Kangchen Pharmaceutical reported a revenue of 461 million CNY, representing a year-on-year growth of 13.79% [2]. - The net profit attributable to shareholders for the same period was 91.046 million CNY, reflecting a year-on-year increase of 14.95% [2]. Group 3: Shareholder and Institutional Holdings - As of June 30, 2025, the number of shareholders decreased by 10.82% to 9,970, while the average circulating shares per person increased by 12.14% to 15,771 shares [2]. - The company has distributed a total of 437 million CNY in dividends since its A-share listing, with 175 million CNY distributed over the past three years [3]. - Notable institutional shareholders include Penghua Medical Technology Stock A, which increased its holdings by 35.46% to 1.3944 million shares, and new entrants like E Fund Healthcare Industry Mixed A and CITIC Securities Medical Reform A [3].

证券日报网讯 9月16日晚间，康辰药业发布关于公司2023年限制性股票激励计划首次授予第二个限售期 解除限售暨上市公告称，本次股票上市类型为股权激励股份；股票认购方式为网下，本次股票上市流通 总数为796，000股。本次股票上市流通日期为2025年9月22日。 （文章来源：证券日报） ...

一、公司 2023 年限制性股票激励计划（简称 "本激励计划"）实施情况 （一）股权激励计划已履行的程序 证券代码：603590 证券简称：康辰药业 公告编号：临 2025-053 北京康辰药业股份有限公司 关于公司 2023 年限制性股票激励计划首次授予 第二个限售期解除限售暨上市公告 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 796,000股。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次股票上市流通总数为796,000股。 重要内容提示： 本次股票上市流通日期为2025 年 9 月 22 日。 8、公司于 2024 年 9 月 29 日，公司召开第四届董事会第十二次会议和第四届 监事会第十次会议，于 2024 年 10 月 29 日召开 2024 年第二次临时股东大会，审 议通过《关于回购注销部分激励对象已获授但尚未解除限售的限制性股票及调整 回购价格的议案》。 1、2023 年 7 月 31 日，公司召开第四届董事会第四次会议、第四届监事会第 三次会议，审议通过《关于公司<2023 年 ...